Inclusion Criteria:  Individuals who meet all of the following criteria are eligible for enrollment as study subjects-  Subject must be able to understand and provide informed consent End stage renal disease (ESRD) on hemodialysis  United Network for Organ Sharing (UNOS) listed listed with current calculated panel reactive antibodies (cPRA) ≥99.9% or >98% (with >5 years of waiting time) awaiting deceased donor transplant  --Note: Those with cPRA >98% with human leukocyte antigen (HLA)-incompatible approved living donor who have not received a transplant after 1 year in a paired kidney exchange program are also eligible  Evidence of established immunity to Epstein-Barr Virus (EBV) as demonstrated by serologic testing  Negative result of most recent tuberculosis (TB) testing or appropriately completed latent TB infection (LTBI) therapy.  Testing should be conducted using either a PPD or interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB) Results from tests performed within 12 months prior to study entry are acceptable in the absence of any intervening exposure to TB Subjects with a positive test for LTBI must complete appropriate therapy for LTBI ---LTBI treatment regimens should be among those endorsed by the Centers for  Disease Control and Prevention (CDC), Division of TB Elimination, url:  https://www.cdc.gov/tb/topic/treatment/ltbi.htm  Negative Food and Drug Administration (FDA)-approved test for human immunodeficiency virus (HIV) diagnosis (at screening or as documented in medical record, up to 12 months prior to screening)  Negative Hepatitis C antibody test at screening or as documented in medical record, up to 12 months prior to screening  --If there is a history of treated hepatitis C or there is a suspected false positive hepatitis C virus (HCV) antibody test, then documentation of two consecutive negative HCV quantitative ribonucleic acid (RNA) Polymerase chain reaction (PCR) tests separated by at least 6 months is required  Negative result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase (RT-PCR) Female subjects of reproductive potential must have a negative pregnancy test upon study entry All subjects of reproductive potential must agree to use of contraception for the duration of the study  Subjects must have current vaccinations or documented immunity to varicella, measles, hepatitis B, pneumococcus, influenza, and zoster (if ≥50 years old)  If subjects require administration of vaccines to meet eligibility requirements, they must wait at least 2 weeks between vaccination and the baseline (Visit 0) visit  Exclusion Criteria:  Individuals who meet any of these criteria are not eligible for enrollment as study subjects-  Inability or unwillingness of a subject to give written informed consent or comply with study protocol Known active current or history of invasive fungal infection or non-tuberculous mycobacterial infection Hepatitis B surface antigen or core antibody positive Serious uncontrolled concomitant major organ disease excluding kidney failure Previous non-kidney solid organ or bone marrow transplant Any infection requiring hospitalization and intravenous (IV) antibiotics within 4 weeks of screening or by mouth (PO) antibiotics within 2 weeks Primary or secondary immunodeficiency History of active tuberculosis (TB), even if treated History of positive result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase (RT-PCR) Malignancy within the last 5 years except treated basal and squamous cell cancer of the skin or treated in situ cervical cancer History of plasma cell dyscrasia Alcohol, drug, or chemical abuse within 1 year Difficult peripheral venous access Need for uninterrupted anticoagulation Neutropenia (absolute neutrophil count <1000/uL) or thrombocytopenia (platelet count <100,000/uL) within 4 weeks prior to study enrollment Women who are currently pregnant or nursing Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of screening Current treatment with other biological drug Immunization with live vaccine within 2 weeks of study baseline (Visit 0) visit  Past or current medical problems or findings from physical examination or laboratory testing not listed above, which, in the opinion of the investigator, may:  pose additional risks from participation in the study, interfere with the subject's ability to comply with study requirements, or impact the quality or interpretation of the data obtained from the study